TARO-BUDESONIDE 0.125 MG
BUDESONIDE : 0.125 MG · DIN 02494264 · TARO PHARMACEUTICALS INC
Health Canada status: MARKETED
What is TARO-BUDESONIDE?
TARO-BUDESONIDE 0.125 MG contains BUDESONIDE : 0.125 MG. It is listed in the Health Canada Drug Product Database under DIN 02494264, held by TARO PHARMACEUTICALS INC, supplied as SUSPENSION for INHALATION administration. Health Canada currently lists it as marketed, status dated 04-Jun-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02494264 |
|---|---|
| Brand name | TARO-BUDESONIDE |
| Generic / active ingredient | BUDESONIDE : 0.125 MG |
| Manufacturer | TARO PHARMACEUTICALS INC |
| Strength | 0.125 MG |
| Dosage form | SUSPENSION |
| Route of administration | INHALATION |
| Schedule | Prescription |
| ATC code | R03BA02 BUDESONIDE |
| AHFS class | 68:04.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 04-Jun-2021 |
| Original market date | 2021-06-04 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code R03BA02 BUDESONIDE. 12 of 12 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| PULMICORT NEBUAMP 0.125 MG/ML | 0.125 MG | SUSPENSION | ASTRAZENECA CANADA INC | MARKETED | DIN 02229099 |
| PULMICORT NEBUAMP 0.25 MG/ML | 0.25 MG | SUSPENSION | ASTRAZENECA CANADA INC | MARKETED | DIN 01978918 |
| PULMICORT NEBUAMP 0.5 MG/ML | 0.5 MG | SUSPENSION | ASTRAZENECA CANADA INC | MARKETED | DIN 01978926 |
| PULMICORT TURBUHALER | 100 MCG | POWDER (METERED DOSE) | ASTRAZENECA CANADA INC | MARKETED | DIN 00852074 |
| PULMICORT TURBUHALER | 200 MCG | POWDER (METERED DOSE) | ASTRAZENECA CANADA INC | MARKETED | DIN 00851752 |
| PULMICORT TURBUHALER | 400 MCG | POWDER (METERED DOSE) | ASTRAZENECA CANADA INC | MARKETED | DIN 00851760 |
| TARO-BUDESONIDE | 0.25 MG | SUSPENSION | TARO PHARMACEUTICALS INC | MARKETED | DIN 02494272 |
| TARO-BUDESONIDE | 0.5 MG | SUSPENSION | TARO PHARMACEUTICALS INC | MARKETED | DIN 02494280 |
| TEVA-BUDESONIDE | 0.125 MG | SUSPENSION | TEVA CANADA LIMITED | MARKETED | DIN 02465949 |
| TEVA-BUDESONIDE | 0.25 MG | SUSPENSION | TEVA CANADA LIMITED | MARKETED | DIN 02535416 |
Who else supplies BUDESONIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BUDESONIDE appears in 1002 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.